Vascular endothelial growth factor (VEGF) promotes various processes involved in angiogenesis, including endothelial cell proliferation, adhesion, migration, and chemotaxis (1). Angiogenesis is a hallmark of cancer (2) and has been targeted by various cancer therapies, with a focused effort on drugs that inhibit VEGF. Several antiangiogenic agents have been approved by the US Food and Drug Administration (FDA) to treat various cancers and other diseases. Bevacizumab (Genentech, South San Francisco, CA), a recombinant humanized monoclonal antibody to VEGF, is approved for the treatment of metastatic colorectal and kidney cancer, glioblastoma, and non-small cell lung cancer. Ziv-aflibercept (Regeneron, Tarrytown, NY), a soluble decoy receptor for VEGF, is an FDA-approved agent for the treatment of metastatic colorectal cancer and is currently in clinical trials for the treatment of several other cancer types. Other FDA-approved antiangiogenic cancer therapeutics include axitinib, pazopanib, regorafenib, sorafenib, and sunitinib. These agents are small molecule kinase inhibitors with various targets such as VEGF receptors, platelet-derived growth factor receptors, fibroblast growth factor receptors, and Raf kinase.
Systems biology approaches are useful in gaining a broader understanding of the complexity of angiogenesis. Computational models can be applied to generate and test biological hypotheses and can aid in the development of effective therapies that target angiogenesis (3) . Additionally, models can provide a framework to predict promising drug targets and identify patient populations that will respond to a particular therapy.
We have developed a molecular-detailed compartment model that is useful in understanding VEGF dynamics in the body. The model is based on detailed biochemical kinetics and molecular transport and has been validated against available experimental data. It is a predictive tool that can provide insight into the distribution of VEGF in the body and the effects of systemic administration of anti-VEGF therapeutics, such as bevacizumab and aflibercept. We have applied the model to understand and explain clinical observations of anti-VEGF agents (4) and predict the effect of the drugs (5, 6) . Here, we present three important model predictions regarding the pretreatment levels of VEGF 121 and VEGF 165 and the dynamic response of plasma and tumor VEGF to anti-VEGF treatment. We compare our results with available experimental data and propose clinical applications of the model predictions.
Methods
The whole-body model includes normal tissue ("normal compartment," represented by skeletal muscle), the vasculature ("blood compartment"), and diseased tissue ("tumor compartment") and has been described in our previous articles (5, 6) . The normal and tumor compartments consist of parenchymal and endothelial cells and interstitial space ( Figure 1A) . We include molecular interactions between two major VEGF isoforms (VEGF 121 and VEGF 165 ), VEGF receptors (VEGFR1 and VEGFR2), and coreceptor neuropilins (NRP1 and NRP2) ( Figure 1B) . In this study, we also include VEGF interactions with two soluble factors: soluble VEGFR1 (sVEGFR1) and α-2-macroglobulin (α2M), introduce VEGF secretion by endothelial cells, and modify the permeability between the blood and tumor. The tumor is parameterized as a breast tumor with a volume of 33 cm 3 ; however, the model is broadly applicable to any solid tumor. Model elements reflect quantitative experimental characterization of the VEGF system. The model is described in detail in the Supplementary Methods (available online).
The model predicts the concentration of 154 species using 154 ordinary differential equations. We are able to predict VEGF level in the multiple tissues in the body as well as the distribution of VEGF in the form of unbound ligand or matrix-and receptorbound complexes. The predicted levels of free VEGF and sVEGFR1 in muscle interstitium (7) (8) (9) (10) (11) (12) (13) and plasma (14) (15) (16) (17) (18) (19) are within the range of experimental data (Table 1 ). We apply the model to predict the effect of VEGF-neutralizing agents used in cancer therapy. We use the kinetic parameters for bevacizumab in our simulations, although the model is applicable to other anti-VEGF macromolecules. We assume that an indicator of the success of anti-VEGF treatment is a reduction in tumor interstitial VEGF. Therefore, we quantify the response to anti-VEGF therapy by calculating the fold-change, which is the level of free VEGF in the tumor interstitium at 3 weeks after administration of the anti-VEGF agent divided by the pretreatment level. A fold-change of less than one indicates that free VEGF in the tumor decreases after treatment and is termed a therapeutic effect; conversely, a foldchange larger than one indicates a countertherapeutic effect.
results

Concentration of Free VEGF in the Tumor Interstitium
The model predicts that at steady state the concentration of free VEGF in the tumor interstitium will be approximately 26 pM (1125 pg/mL), based on microvascular permeability between the tumor and blood on the order of 10 −7 cm/s, termed low permeability. In the case of high permeability on the order of 10 −5 cm/s, based on the data in Chauhan et al. (20) , free VEGF in the tumor is predicted to be 13 pM (585 pg/mL). Plasma VEGF is approximately 2 pM in cancer patients (15). Thus, the predicted level of free VEGF in the tumor is an order of magnitude (ie, 7 to 13 times) larger than the level of plasma VEGF.
The predicted ratio of tumor interstitial VEGF to plasma VEGF compares well with available experimental data. Although little if any quantitative data are available for the concentration of VEGF in the tumor interstitial fluid, numerous studies have quantified VEGF in tumor ascites fluid and pleural effusions (21−46), which contain proteins derived from the extracellular compartment (47) and should reflect the level of free VEGF. A compilation of these studies is presented in Supplementary Table 1 (available online). Some of the studies also report the concentration of VEGF in the serum or plasma of the patients. These data show that free VEGF in the tumor is two to 10 times larger than the VEGF concentration in serum or plasma across several cancer types ( Figure 2 ). In contrast, microdialysis measurements of tumor interstitial fluid show that tumor extracellular VEGF is approximately 1 pM (48); however, this method may underestimate VEGF because it is unable to completely recover high molecular weight compounds (49) . Thus, our model predictions that free VEGF in the tumor can be seven to 13 times higher than plasma VEGF agree with experimental evidence from tumor fluid. Although the experimental data are highly variable and may be subject to artifacts intrinsic to microdialysis and enzyme-linked immunosorbent assay (ELISA) methods, they provide a basis for validating the model predictions.
Predominant Isoform in the Tumor Interstitium
In our model, the VEGF isoforms VEGF 121 and VEGF 165 are secreted by tumor cells in equal amounts (6) based on experimental data (50) (51) (52) (53) . Notably, this ratio of VEGF 121 to VEGF 165 secretion is different from that in skeletal muscle, where it is heavily skewed toward the secretion of the heparin-binding isoform, approximately 8:92 (54) . Despite the 50:50 tumor secretion ratio, the model predicts that VEGF 121 accounts for 81% or 71% of free VEGF in the tumor interstitium for low and high tumor permeability, respectively ( Figure 3 ). This prediction is a direct result of the different binding profiles of the isoforms. VEGF 165 is able to bind to glycosaminoglycan (GAG) chains in the extracellular matrix (ECM) and basement membranes (55) and can directly bind to NRPs (56), which are highly expressed on endothelial and parenchymal cells. In contrast, VEGF 121 cannot be sequestered by the ECM or basement membranes (55) and does not directly bind to NRPs. For these reasons, a large percentage of free VEGF is VEGF 121 .
Experimental measurements of VEGF at the protein level support the model predictions. Poon et al. showed that VEGF 165 accounts for 27% of total VEGF (free and bound) in the tumor cytosol for hepatocellular carcinoma patients (57, 58) . Additionally, a novel ELISA enables quantification of specific VEGF isoforms and was applied to measure the shorter, soluble VEGF isoforms VEGF 110 and VEGF 121 in tumor lysates from patients with ovarian cancer (59) . The data from that study (59) showed that the mean relative amount of VEGF 165 in tumor lysates ranged from 24% to 31%. These data suggest that VEGF 165 is not the predominant isoform in the tumor and support the model predictions.
Tumor Interstitial Free VEGF After Administration of Bevacizumab
We are interested in predicting the levels of free VEGF in the body after anti-VEGF treatment. Counterintuitively, measurements of VEGF levels in plasma show that circulating VEGF increases after treatment (60) (61) (62) . We previously applied the model to investigate the mechanism by which plasma VEGF increases after treatment and predicted that the increase is due to the intercompartment transport of VEGF, anti-VEGF, and the VEGF/anti-VEGF complex (4). The tumor model also predicted that free VEGF in the tumor decreased with anti-VEGF treatment (4). Based on those results, we hypothesized that the mechanism of action of anti-VEGF agents is to deplete tumor VEGF rather than circulating intravascular VEGF. It is important to neutralize free VEGF in the tumor because this pool of VEGF can stimulate angiogenesis by binding to and activating abluminal endothelial cell receptors in the tumor. It is also possible for VEGF to promote tumor growth by activating receptors localized on tumor cells, which may or may not be angiogenesis dependent (63, 64) . Additionally, VEGF can stimulate intracellular pools of VEGFR1 and VEGFR2 by intracrine signaling (65, 66) .Therefore, we have investigated the response of tumor VEGF to anti-VEGF treatment while varying properties of the tumor microenvironment. The model predicts that tumor-specific properties influence the behavior of free VEGF in the tumor interstitium after anti-VEGF treatment (6) . We have varied the density of VEGF receptors and coreceptors on tumor cells and investigated how receptor density influences the response to anti-VEGF therapy. The model predicts that the response of tumor VEGF to the anti-VEGF treatment is robust across a wide range of receptor expression levels, where free VEGF in the tumor is depleted after treatment ( Figure 4A ).
VEGF levels in the tumor after anti-VEGF therapy are sensitive to the relative rate at which the VEGF isoforms are secreted by tumor cells. We varied the relative amount of VEGF 121 secreted by tumor cells from zero to 100% to determine how this tumorspecific property affects the level of free VEGF in the tumor after anti-VEGF treatment. Model simulations indicate that the VEGF isoform secretion ratio in the tumor impacts the response to anti-VEGF treatment ( Figure 4B ). In all cases, free VEGF in the tumor is predicted to decrease after treatment. Interestingly, for tumors that secrete only VEGF 165 and have high NRP expression, free VEGF in the tumor is nearly unchanged 3 weeks after the anti-VEGF is administered, as compared with the pretreatment level.
The response of free VEGF in the tumor depends on the absolute rate of VEGF secretion by tumor cells. We varied the rate of VEGF secretion in the tumor from the baseline value, which was set by in vitro measurements, while keeping the isoform secretion ratio at 50:50. Counterintuitively, the model predicted that free VEGF in the tumor can increase after treatment, specifically in tumors that secrete low amounts of VEGF ( Figure 4C ).
Our simulation results indicate that tumor VEGF can decrease after treatment and identifies conditions under which free VEGF in both plasma and tumor increase with anti-VEGF treatment ( Figure 5A ). The tumor response to anti-VEGF treatment can be interpreted with a detailed quantitative analysis of the intercompartmental flows and VEGF/anti-VEGF binding reaction, which is divided into two temporal phases ( Figure 5B ). In the first phase after injection of the anti-VEGF, the drug binds to free VEGF in the plasma, leading to a depletion of plasma VEGF. Unbound anti-VEGF extravasates to the tissue compartments, where it binds to and depletes interstitial VEGF. There are two possibilities for the second phase. In the first, termed phase 2A, the anti-VEGF/VEGF complex in the tissue compartments is transported into the blood. Because of the species concentrations and reversal of the direction of the anti-VEGF binding reaction in the plasma, free VEGF accumulates in the plasma, leading to an increase in plasma VEGF above the pretreatment level. Alternatively, in phase 2B, plasma VEGF increases above the pretreatment level, and tumor VEGF can increase above the pretreatment level. The increase in free VEGF in the tumor is due to extravasation of free VEGF and the anti-VEGF/VEGF complex to the tumor, combined with a net unbinding of the complex in the tumor. These phenomena result from concentration differences among free VEGF, free anti-VEGF, and the anti-VEGF/VEGF complex in the tumor and blood. In summary, the mechanisms by which free VEGF in plasma and tumor increase above the pretreatment level are explained by biochemical and transport processes.
There is a scarcity of data on the response of tumor VEGF to anti-VEGF treatment with which to compare the model results. Studies performed in mice have conflicting results (67) (68) (69) (70) . To the to the drug, where the level of free VEGF in the tumor at 3 weeks is decreased, as compared with the pretreatment level. Right panel shows countertherapeutic response, where administration of the drug leads to an increase in free VEGF in the tumor. B) Dynamic levels of free VEGF can be explained by the intercompartment flows and direction of VEGF/anti-VEGF binding reaction. Phase 1: After intravenous administration of the anti-VEGF agent, the agent binds free VEGF in the plasma, leading to a substantial depletion of plasma VEGF. Unbound anti-VEGF partially extravasates to the tissue compartments to bind and deplete interstitial VEGF. In the subsequent phases, both plasma and tumor VEGF begin to increase. Phase 2A: The anti-VEGF/VEGF complex intravasates from the tissue compartments, and the direction of the anti-VEGF binding reaction in the plasma reverses (indicated by red arrow), leading to an increase in plasma VEGF above the pretreatment level. Phase 2B: Extravasation of free VEGF and the anti-VEGF/VEGF complex from blood to tumor, along with a reversal of the direction of the anti-VEGF binding reaction in the tumor leads to an increase in tumor VEGF. Depending on the initial level of interstitial tumor VEGF (determined by the tumor microenvironment), these factors could lead to an increase above the pretreatment level. Plasma VEGF increases above the pretreatment level.
Discussion
Model Limitations
We have not considered the role of additional VEGF isoforms such as VEGF 189 , which has been shown to be involved in tumor angiogenesis (71) or VEGF xxxb isoforms, which modulate vascularization and can be antiangiogenic (72) (73) (74) (75) or weakly proangiogenic (76) . However, there is limited quantitative information available on the rate at which these isoforms are secreted by parenchymal cells. Additionally, we have not included blood platelets, which are known to be a rich source of angiogenic factors (77, 78) and are able to sequester bevacizumab (79) . We assume the normal compartment is skeletal muscle because this composes a large percentage of the body weight in humans. Other tissues and organs have been shown to contain VEGF (80, 81) ; however, quantitative experimental data for the geometric properties, VEGF secretion rate, and density of VEGF receptors in these tissues are largely unavailable. Lastly, although bevacizumab is given with chemotherapy for most cancer types, leading to a reduction in tumor size, we assume a constant tumor size of 33 cm 3 . The model predicts that for a tumor that is 100 times larger (ie, 3300 cm 3 ), the concentration of free VEGF in the normal and tumor tissues increases by less than 1%. Plasma VEGF increases 1.5-fold. Therefore, we do not expect that simulating a tumor whose size is dynamic will qualitatively change the model predictions or the conclusions drawn.
The model can be further expanded to include the elements described above as quantitative experimental data become available. It is possible that the absence of one or more of these elements from the model contributes to the counterintuitive prediction that both plasma and tumor VEGF can increase after anti-VEGF treatment. However, we believe that the current model is a minimal, experiment-based model that includes important factors that contribute to VEGF transport and kinetics in the body. The model qualitatively and quantitatively describes the living system and clinical observations. Therefore, we present our results and their clinical implications based on the current state of the model.
Clinical Relevance of Model Predictions
Implication of High Tumor Interstitial VEGF. The model predicts that unbound VEGF in the tumor interstitium can be an order of magnitude (ie, 7-13 times) higher than plasma VEGF for the range of parameters we considered. This prediction, which is in agreement with experimental data, implies that VEGF signaling in endothelial cells is likely to be dominated by the abluminal rather than luminal VEGF receptors. It diminishes the role of luminal VEGF concentration and emphasizes the role of interstitial tumor concentration. Thus, depleting tumor VEGF may be an important target for antiangiogenic therapies.
Implication of the Predominance of VEGF 121 Isoform. Our model predicts that VEGF 121 is a predominant isoform in the tumor interstitium, which may be important to consider when developing treatment strategies that target VEGF. Prior quantitative analysis has shown that targeting this isoform is predicted to result in a therapeutic effect (5) . Experimental studies in tumorbearing mice demonstrate that VEGF 121 -expressing tumors recruit host vasculature (82) and have increased vascular volume (83) compared with tumors that secrete other isoforms such as VEGF 165 or VEGF 189 . These studies indicate that VEGF 121 is a key regulator of tumor angiogenesis, and our model supports this finding.
Implication of Therapeutic or Countertherapeutic Response
to Anti-VEGF Treatment. Our analysis reveals that, depending on the tumor microenvironment, anti-VEGF treatment can have adverse effects of slightly increasing free VEGF in the tumor or not affecting tumor VEGF at all. Incorporating properties of the microenvironment for specific tumor types allows us to investigate why certain tumors respond more favorably to anti-VEGF treatment than others. This prediction would be very instructive in understanding clinical data, including the lack of efficacy of anti-VEGF treatment in specific tumor types or for specific groups of patients, and may aid in the design of future clinical trials. It may lead to stratification of patients into likely responders vs nonresponders based on their microenvironmental parameters and even to personalized medical treatment. An important example is the use of anti-VEGF treatment in breast cancer patients, for which the FDA has revoked approval of bevacizumab for this indication. As shown in Figure 2 and Supplementary Table 1 (available online), the median level of free VEGF in tumor fluids of breast cancer patients is 20 pM; however, the concentration ranges from 1.7 pM to 320 pM (30) . The low end of this range corresponds with the low secretion rates shown in Figure 4C , where free VEGF in the tumor is predicted to increase above the pretreatment level after anti-VEGF treatment. This example supports the importance of our model predictions, which indicate that anti-VEGF treatment may lead to countertherapeutic results in certain subpopulations of cancer patients, even those with the same type of cancer. The concentration of VEGF 121 is being explored as a biomarker in retrospective studies (84, 85) . Additionally, VEGFR and NRP expression levels have been investigated as a predictive biomarker in breast (86) and gastric (87) cancers. Thus, our computational studies complement clinical investigations.
In conclusion, our molecular-detailed computational model is useful for understanding the dynamics of VEGF distribution in the body. The model predictions are relevant to the clinical use of VEGF-targeting therapies and testable hypotheses that can aid in elucidating the mechanism of action of anti-VEGF agents. Further experimental and computational studies will need to test whether these predictions are applicable to different cancer types, to primary tumors and metastasis, and to diverse or specific patient populations and whether they can guide personalized medicine. In anticipation of these measurements, we expect that our model predictions will lead to conceptual assessment of the different outcomes of antiangiogenic treatments and will encourage clinical researchers to consider tumor-specific properties that will influence the response to treatment. 
